Skip to main content
BioCardia, Inc. logo

BioCardia, Inc. — Investor Relations & Filings

Ticker · BCDA ISIN · US09060U5074 LEI · 5493003EDBXRQRW22O75 US Manufacturing
Open in API
Filings indexed 1,023 across all filing types
Latest filing 2016-10-17 Interim / Quarterly Rep…
Country US United States of America
Listing US BCDA

About BioCardia, Inc.

https://www.biocardia.com/

BioCardia, Inc. is a clinical-stage regenerative medicine company that develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. The company's lead program is the CardiAMP® cell therapy system, an autologous therapy that uses a patient's own bone marrow cells to potentially stimulate the body's natural healing response in the heart. This therapy is primarily being evaluated for the treatment of ischemic heart failure. In addition to its autologous platform, BioCardia is also developing CardiALLO™, an allogeneic cell therapy platform using cells from qualified donors. The company's approach integrates biotherapeutic candidates with proprietary delivery systems for targeted administration.

Recent filings

Filing Released Lang Actions
10-Q
Interim / Quarterly Report 9M 2016
2016-10-17 English
SCHEDULE 14F
Board/Management Information Classification · 95% confidence The document is titled 'SCHEDULE 14F-1 INFORMATION STATEMENT' pursuant to Section 14(f) of the Securities Exchange Act of 1934 and Rule 14f-1. It is an information statement related to a change in majority control of the Board of Directors of Tiger X Medical, Inc. The document details the merger agreement, the resulting change in board members, executive officers, and ownership structure. It explicitly states that no shareholder vote is required and that proxies are not being solicited. The content focuses on the change in board composition and control due to the merger, including detailed ownership tables and lock-up agreements. This matches the description of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management. The document is not a full annual report, audit report, or earnings release, nor is it a proxy solicitation or voting results announcement. Therefore, the correct classification is MANG with high confidence.
2016-10-07 English
FORM 8-K
M&A Activity Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The content describes the entry into a material definitive agreement, specifically a merger agreement between Tiger X Medical, Inc. and BioCardia, Inc. It details the terms of the merger, conditions, and related information. There is no full financial report or earnings data, but rather an announcement of a significant corporate transaction. This fits the category of M&A Activity filings, which cover announcements and documents related to merger proposals or takeover bids. The document length is sufficient and contains detailed merger information, not just a brief announcement or press release. Therefore, the appropriate classification is M&A Activity (TAR).
2016-08-25 English
FORM 4 SUBMISSION
Director's Dealing
2016-08-12 English
FORM 4 SUBMISSION
Director's Dealing
2016-08-12 English
FORM 4 SUBMISSION
Director's Dealing
2016-08-12 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.